The analysis of millions of genetic variants in over 1000 individuals from a Mediterranean population is revealing known pathogenic genetic variants which will facilitate genetic diagnostics in the region.
Whereas previously we had to test every candidate genetic variant in a few hundred samples we can now rapidly determine the frequency of any variant in the Maltese using the TargetID genomic data. Together with the medical and family history, and extensive laboratory and physical measurements, as well as ten-year follow up data on all the participants from the Maltese Acute Myocardial Infarction (MAMI) Study makes it simpler and faster to determine if a gene is disease-causing. This helps us reach our overall goal to give tools to clinicians and researchers to improve healthcare.
TargetID: Novel Drug Targets for Infectious Diseases is a University of Malta #UM project funded through the #MCST COVID-19 R&D Fund 2020 jointly administered by the Malta Council for Science & Technology and Malta Enterprise.
The MAMI Study was conducted as a collaboration between the University of Malta and the Malta Department of Health. The sample and data collection was funded through the MCST R&I 2008 programme and a number of Malta Government Scholarship Scheme (MGSS) grants.
